AU2013201780B2 - Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof - Google Patents

Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Download PDF

Info

Publication number
AU2013201780B2
AU2013201780B2 AU2013201780A AU2013201780A AU2013201780B2 AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2 AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 A AU2013201780 A AU 2013201780A AU 2013201780 B2 AU2013201780 B2 AU 2013201780B2
Authority
AU
Australia
Prior art keywords
compound
formula
disease
mmol
oxa
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
AU2013201780A
Other languages
English (en)
Other versions
AU2013201780A1 (en
Inventor
Christopher John Burns
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YM Biosciences Australia Pty Ltd
Original Assignee
YM Biosciences Australia Pty Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by YM Biosciences Australia Pty Ltd filed Critical YM Biosciences Australia Pty Ltd
Priority to NZ703343A priority Critical patent/NZ703343A/en
Priority to PT138097399T priority patent/PT2867238T/pt
Priority to HK15109468.7A priority patent/HK1208861A1/xx
Priority to ES13809739.9T priority patent/ES2644606T3/es
Priority to PCT/AU2013/000687 priority patent/WO2014000032A1/en
Priority to JP2015518724A priority patent/JP5931288B2/ja
Priority to CN201380041191.XA priority patent/CN104583216A/zh
Priority to CA2877923A priority patent/CA2877923C/en
Priority to EP13809739.9A priority patent/EP2867238B1/en
Priority to HK15109881.6A priority patent/HK1209120B/en
Publication of AU2013201780A1 publication Critical patent/AU2013201780A1/en
Application granted granted Critical
Publication of AU2013201780B2 publication Critical patent/AU2013201780B2/en
Priority to JP2015178970A priority patent/JP6153980B2/ja
Ceased legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A61P29/02—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] without antiinflammatory effect
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/08—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing alicyclic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Oncology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
AU2013201780A 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof Ceased AU2013201780B2 (en)

Priority Applications (11)

Application Number Priority Date Filing Date Title
CN201380041191.XA CN104583216A (zh) 2012-06-29 2013-06-26 苯基氨基嘧啶双环化合物及其用途
HK15109468.7A HK1208861A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
ES13809739.9T ES2644606T3 (es) 2012-06-29 2013-06-26 Compuestos bicíclicos de fenil amino pirimidina y usos de los mismos
PCT/AU2013/000687 WO2014000032A1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
JP2015518724A JP5931288B2 (ja) 2012-06-29 2013-06-26 フェニルアミノピリミジン二環式化合物およびその使用
CA2877923A CA2877923C (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
NZ703343A NZ703343A (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
EP13809739.9A EP2867238B1 (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
PT138097399T PT2867238T (pt) 2012-06-29 2013-06-26 Compostos bicíclicos de fenil amino pirimidina e utilizações dos mesmos
HK15109881.6A HK1209120B (en) 2012-06-29 2013-06-26 Phenyl amino pyrimidine bicyclic compounds and uses thereof
JP2015178970A JP6153980B2 (ja) 2012-06-29 2015-09-10 フェニルアミノピリミジン二環式化合物およびその使用

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261666725P 2012-06-29 2012-06-29
US61/666,725 2012-06-29

Publications (2)

Publication Number Publication Date
AU2013201780A1 AU2013201780A1 (en) 2014-01-16
AU2013201780B2 true AU2013201780B2 (en) 2015-04-02

Family

ID=49778746

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2013201780A Ceased AU2013201780B2 (en) 2012-06-29 2013-03-21 Phenyl Amino Pyrimidine Bicyclic Compounds And Uses Thereof

Country Status (11)

Country Link
US (1) US8809359B2 (enExample)
EP (1) EP2867238B1 (enExample)
JP (2) JP5931288B2 (enExample)
CN (1) CN104583216A (enExample)
AU (1) AU2013201780B2 (enExample)
CA (1) CA2877923C (enExample)
ES (1) ES2644606T3 (enExample)
HK (1) HK1208861A1 (enExample)
NZ (1) NZ703343A (enExample)
PT (1) PT2867238T (enExample)
WO (1) WO2014000032A1 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HUE029188T2 (en) 2007-03-12 2017-03-28 Ym Biosciences Australia Pty Phenylamino-pyrimidine compounds and their use
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof
TWI681954B (zh) 2014-06-12 2020-01-11 美商西爾拉癌症醫學公司 Ｎ-（氰基甲基）-４-（２-（４-𠰌啉基苯基胺基）嘧啶-４-基）苯甲醯胺
EP3255129B1 (en) * 2016-06-06 2024-01-24 The Lubrizol Corporation Thiol-carboxylic adducts as lubricating additives
CN108707119A (zh) * 2018-06-25 2018-10-26 抚顺大恒化工有限公司 一种Momelotinib的制备方法
CA3156007A1 (en) 2019-09-27 2021-04-01 Disc Medicine, Inc. METHODS OF TREATING MYELOFIBROSE AND ASSOCIATED CONDITIONS
CN111100076A (zh) * 2019-12-30 2020-05-05 武汉九州钰民医药科技有限公司 Jak抑制剂莫美洛替尼的制备方法
AU2021273014A1 (en) 2020-05-13 2022-11-17 AbbVie Deutschland GmbH & Co. KG Anti-hemojuvelin (HJV) antibodies for treating anemia of chronic disease
ES3075793T3 (en) 2020-05-13 2026-08-07 Disc Medicine Inc Anti-hemojuvelin (hjv) antibodies for treating myelofibrosis
EP3944859A1 (en) 2020-07-30 2022-02-02 Assistance Publique Hôpitaux de Paris Method for treating immune toxicities induced by immune checkpoint inhibitors
CN117624189B (zh) * 2023-11-24 2025-11-11 上海馨远医药科技有限公司 一种6-氧杂-3-氮杂双环[3.1.1]庚烷盐酸盐的制备方法
CN117986179A (zh) * 2024-01-16 2024-05-07 深圳市茵诺圣生物科技有限公司 一种顺式-4-羟基-l-脯氨酸的合成方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3481932A (en) 1967-09-01 1969-12-02 Searle & Co 2-anilino-5-methyl-6-phenylpyrimidines and congeners
GB9523675D0 (en) 1995-11-20 1996-01-24 Celltech Therapeutics Ltd Chemical compounds
GB9914258D0 (en) 1999-06-18 1999-08-18 Celltech Therapeutics Ltd Chemical compounds
GB9924862D0 (en) 1999-10-20 1999-12-22 Celltech Therapeutics Ltd Chemical compounds
US7122544B2 (en) 2000-12-06 2006-10-17 Signal Pharmaceuticals, Llc Anilinopyrimidine derivatives as IKK inhibitors and compositions and methods related thereto
MXPA03008888A (es) 2001-03-29 2005-03-07 Vertex Pharma Inhibidores de n-terminal c-jun cinasas (jnk) y otras proteinas cinasas.
US6433018B1 (en) 2001-08-31 2002-08-13 The Research Foundation Of State University Of New York Method for reducing hypertrophy and ischemia
CA2459794C (en) 2001-09-12 2012-08-21 Virexx Medical Corp. Vascular occlusion solid-phase agent with immobilised platelet binding agent
AU2003262642B2 (en) 2002-08-14 2010-06-17 Vertex Pharmaceuticals Incorporated Protein kinase inhibitors and uses thereof
EP1562911B1 (en) 2002-11-01 2010-01-06 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of jak and other protein kinases
US7259161B2 (en) 2002-11-04 2007-08-21 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
US7348335B2 (en) 2002-11-05 2008-03-25 Vertex Pharmaceuticals Incorporated Compositions useful as inhibitors of JAK and other protein kinases
GB0317841D0 (en) 2003-07-30 2003-09-03 Cyclacel Ltd Compound
EP1648875A1 (en) 2003-07-30 2006-04-26 Cyclacel Limited 2-aminophenyl-4-phenylpyrimidines as kinase inhibitors
US7799915B2 (en) 2004-10-13 2010-09-21 Wyeth Llc Anilino-pyrimidine analogs
US7593820B2 (en) 2005-05-12 2009-09-22 Cytopia Research Pty Ltd Crystal structure of human Janus Kinase 2 (JAK2) and uses thereof
EA200870217A1 (ru) 2006-01-30 2009-02-27 Экселиксис, Инк. 4-арил-2-аминопиримидины или 4-арил-2-аминоалкилпиримидины в качестве модуляторов jak-2 и содержащие их фармацевтические композиции
BRPI0708347A2 (pt) 2006-02-28 2011-05-24 Cytopia Res Pty Ltd inibição jak2 como um tratamento da hipertensão arterial pulmonar
FR2911139A1 (fr) 2007-01-05 2008-07-11 Sanofi Aventis Sa Nouveaux derives de phenyl-(4-phenyl-pyrimidin-2-yl)amines, leur preparation a titre de medicaments, compositions pharmaceutiques et notamment comme inhibiteurs de ikk
EP2200436B1 (en) 2007-09-04 2015-01-21 The Scripps Research Institute Substituted pyrimidinyl-amines as protein kinase inhibitors
EA020777B1 (ru) * 2007-11-16 2015-01-30 Инсайт Корпорейшн 4-пиразолил-n-арилпиримидин-2-амины, 4-пиразолил-n-пиразолилпиримидин-2-амины и 4-пиразолил-n-пиридилпиримидин-2-амины в качестве ингибиторов киназ janus
HRP20170317T1 (hr) * 2008-02-15 2017-04-21 Rigel Pharmaceuticals, Inc. Spojevi pirimidin-2-amina i njihova uporaba kao inhibitora jak kinaza
BRPI0917575A2 (pt) 2008-08-05 2019-09-24 Targegen Inc métodos de tratamento de talassemia
US20130096104A1 (en) * 2010-03-17 2013-04-18 Genentech, Inc. Imidazopyridine compounds, compositions and methods of use
EA201390815A1 (ru) 2010-12-03 2013-12-30 Им Байосайенсиз Острелиа Пти Лтд. Лечение jak2-опосредованных состояний
SG194212A1 (en) 2011-05-02 2013-11-29 Ym Biosciences Australia Pty Multiple myeloma treatment
US8809359B2 (en) 2012-06-29 2014-08-19 Ym Biosciences Australia Pty Ltd Phenyl amino pyrimidine bicyclic compounds and uses thereof

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008109943A1 (en) * 2007-03-12 2008-09-18 Cytopia Research Pty Ltd Phenyl amino pyrimidine compounds and uses thereof
WO2009029998A1 (en) * 2007-09-06 2009-03-12 Cytopia Research Pty Ltd Retrometabolic compounds

Also Published As

Publication number Publication date
JP5931288B2 (ja) 2016-06-08
JP2015525738A (ja) 2015-09-07
EP2867238B1 (en) 2017-08-09
CA2877923C (en) 2017-07-25
JP2016028076A (ja) 2016-02-25
US8809359B2 (en) 2014-08-19
US20140005161A1 (en) 2014-01-02
EP2867238A4 (en) 2015-05-06
CN104583216A (zh) 2015-04-29
NZ703343A (en) 2015-12-24
CA2877923A1 (en) 2014-01-03
HK1208861A1 (en) 2016-03-18
JP6153980B2 (ja) 2017-06-28
HK1209120A1 (en) 2016-03-24
PT2867238T (pt) 2017-10-30
AU2013201780A1 (en) 2014-01-16
ES2644606T3 (es) 2017-11-29
WO2014000032A1 (en) 2014-01-03
EP2867238A1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
EP2867238B1 (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
AU2008210266B2 (en) Thiopyrimidine-based compounds and uses thereof
AU2008226327B2 (en) Phenyl amino pyrimidine compounds and uses thereof
EP2215094B1 (en) N-containing heterocyclic compounds
TWI879811B (zh) 作為免疫調節劑之吡啶并[3,2-d]嘧啶化合物
JP2017503834A (ja) 炎症性疾患治療のためのベンゾイミダゾール誘導体及びその医薬組成物
AU2016200866B2 (en) Phenyl amino pyrimidine compounds and uses thereof
HK1209120B (en) Phenyl amino pyrimidine bicyclic compounds and uses thereof
AU2013201306B2 (en) Phenyl Amino Pyrimidine Compounds and Uses Thereof
KR102511209B1 (ko) 벤즈이미다졸 유도체 및 염증 질환의 치료를 위한 그의 약학 조성물
RU2785126C2 (ru) Новые соединения и их фармацевтические композиции для лечения воспалительных заболеваний
TW202313014A (zh) 作為ｐｄ－ｌ１相互作用的免疫調節劑的雜環化合物
AU2013248233A1 (en) N-containing heterocyclic compounds
HK1147252B (en) N-containing heterocyclic compounds
HK1223619A1 (en) Phenylaminopyrimidine compound and use thereof
AU2013263739A1 (en) Thiopyrimidine-based Compounds And Uses Thereof

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)
MK14 Patent ceased section 143(a) (annual fees not paid) or expired